๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Adebrelimab + Apatinib in SCLC Maintenance Therapy
NCT06475209SCLC
Tang-Du Hospital
Phase 2
60
Xi'an
2024-06-20
Not yet open
Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy
NCT06442605Leiomyoma, Uterine
First People's Hospital of Hangzhou
Not applicable
22
Hangzhou
2024-06-20
Recruiting
A Trial on the Recurrence Free Survival Rate of Type I AIP With High-risk of Recurrence
NCT06468709Type 1 AIP
Ruijin Hospital
Phase 4
86
Shanghai
2024-06-20
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Merck Sharp & Dohme LLC
Phase 1/2
220
Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu
2024-06-20
Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
NCT06484556Tumor, Solid
Tao Zhang
Phase 1
9
Wuhan
2024-06-19
Active, closed
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
NCT06433531Generalized Pustular Psoriasis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
9
Beijing, Guangzhou, Shijiazhuang, Shenyang, Chengdu, Hangzhou
2024-06-19
Recruiting
Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma
NCT06470217Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
116
Shanghai
2024-06-19
Recruiting
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
NCT06452602Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2024-06-19
Not yet open
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction
NCT06469060Esophageal Cancer
Shanghai Chest Hospital
Phase 2
34
Shanghai
2024-06-19
Recruiting
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06341335Gastric and Gastroesophageal Junction Adenocarcinoma
Akeso
Phase 3
506
Beijing
2024-06-19
Recruiting
RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
NCT06341400Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Zhujiang Hospital
Phase 1/2
55
Guangzhou
2024-06-19
Recruiting
Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)
NCT06452147Anesthesia, Hip Fractures, Dementia, Cognitive Impairment
Second Affiliated Hospital of Wenzhou Medical University
Not applicable
1,860
Wenzhou
2024-06-19
Recruiting
A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
NCT06468358Solid Tumor
L & L Bio Co., Ltd., Ningbo, China
Phase 1/2
194
Shanghai
2024-06-19
Recruiting
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
NCT06368921Solid Tumor
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1
30
Guangzhou, Zhengzhou, Jinan
2024-06-19
Recruiting
A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
NCT06106906Systemic Lupus Erythematosus
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
15
Wuhan
2024-06-19
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
Celgene
Phase 3
850
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou
2024-06-19
Active, closed
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
NCT06445400HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
83
Guangzhou
2024-06-19
Recruiting
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
NCT06455410Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase EARLY_PHASE1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Active, closed
To Compare Efficacy and Safety of CMAB007 and Xolairยฎ in Patients With Chronic Spontaneous Urticaria
NCT06365879Chronic Spontaneous Urticaria
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3
392
Shanghai
2024-06-18
Recruiting
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
NCT07584954Solid Tumor Cancer, Solid Tumor Cancer Treatment With Immunotherapy
Jun Zhou
Phase 1
90
Fuzhou, Anyang, Jinan, Shanghai
2024-06-18
Recruiting
A Long-term Follow-up Study in Participants Who Received CS-101
NCT06479616Beta-Thalassemia
Children's Hospital of Fudan University
Not applicable
5
Shanghai
2024-06-18
Recruiting
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
NCT06316856T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2024-06-18
Recruiting
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
NCT06471257Asthma
AstraZeneca
Phase 3
1,000
Baotou, Beijing, Changchun, Changsha, Chengdu, Chizhou, Chongqing, Dazhou
2024-06-17
Recruiting
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
NCT06427239Pancreatic Cancer
Fudan University
Phase 1/2
130
Shanghai
2024-06-17
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
Boehringer Ingelheim
Phase 3
6,000
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Dalian
2024-06-17
Recruiting
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
NCT06385730Esophageal Cancer
Shanghai Chest Hospital
Phase 2
60
Shanghai
2024-06-17
Recruiting
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
NCT06378593Solid Tumors With FGFR2 Alterations, Adult
3H (Suzhou) Pharmaceuticals Co., Ltd.
Phase 1/2
130
Beijing, Shanghai
2024-06-17
Recruiting
the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children
NCT05911893Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition
Children's Hospital of Chongqing Medical University
Not applicable
200
Hefei, Beijing, Jilin City, Chongqing, Guangzhou, Guiyang, Changsha, Nanjing
2024-06-17
Active, closed
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
NCT05562947Neovascular Age-related Macular Degeneration, nAMD
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Recruiting
Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia
NCT06537115Sarcopenia
Zhejiang Provincial People's Hospital
Phase 4
450
Hangzhou, Huzhou, Taizhou, Zhoushan
2024-06-16
Active, closed
Mesenteric Lymph Node Metastasis and Nutritional Status After Bowel Resection for Ovarian Cancer
NCT06527001Progression-Free Survival, Overall Survival, Nutrition Aspect of Cancer
Anhui Provincial Hospital
Observational
300
Hefei
2024-06-16
Recruiting
Endovascular Treatment for eXtra-Large Ischemic Stroke
NCT06388148Stroke, Acute Ischemic
Zhongming Qiu
Not applicable
286
Hengyang, Xiangtan
2024-06-16
Recruiting
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression
NCT06708156Myopia, Myopia Progression
Oupushifang Pharmaceutical Technology Co., Ltd.
Phase 3
606
Hefei, Xuancheng, Lanzhou, Liuzhou, Nanning, Guiyang, Zunyi, Daqing
2024-06-15
Recruiting
Application of HFNC for the Prevention of Hypoxemia During Perioperative Anesthetic-induced Intubation in Children: A Randomized Controlled Clinical Trial
NCT06425406High-flow Nasal Cannula, Children, Pre-oxygenation
Henan Provincial People's Hospital
Not applicable
48
Zhengzhou
2024-06-15
Recruiting
Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis
NCT06225752Ischemic Stroke, TIA
First Affiliated Hospital of Wannan Medical College
Phase 3
5,452
Wuhu
2024-06-15
Recruiting
Organ Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy
NCT06380842Necrotizing Pancreatitis
Chunling Jiang
Observational
200
Chengdu
2024-06-15
Not yet open
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus
NCT06468683Lupus Erythematosis
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1
50
Shanghai
2024-06-15
Recruiting
Nursing Interventions for Alzheimer's Patients During PET/CT Imaging
NCT06784830Alzheimer's Disease
Sichuan Provincial People's Hospital
Not applicable
200
Chengdu
2024-06-15
Recruiting
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
NCT06597526Peritoneal Metastasis, Gastric Cancer
Ruijin Hospital
Observational
30
Shanghai
2024-06-15
Recruiting
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
NCT06418477Monoclonal Gammopathy of Renal Significance
Peking University People's Hospital
Phase 2
20
Beijing, Guangzhou
2024-06-15
Not yet open
Phase IV Study of Concomitant Administration of the sIPV and HepA
NCT06460545Polio, Hepatitis A
Institute of Medical Biology, Chinese Academy of Medical Sciences
Phase 4
2,000
Chongqing
2024-06-15
Recruiting
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
NCT06454448Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
20
Tianjin
2024-06-15
Recruiting
A Study of IBI363 in Subjects With Advanced Malignancies
NCT06468098Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
556
Shanghai
2024-06-15
Recruiting
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
NCT06378242High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd.
Phase 1/2
24
Guangzhou, Wuhan, Changsha, Nanjing, Chengdu, Tianjin
2024-06-14
Recruiting
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
NCT06508983Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd.
Phase 3
360
Beijing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Suzhou, Taiyuan, Xiโ€™an
2024-06-14
Recruiting
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06461910Gastric Cancer, Esophagogastric Junction Adenocarcinoma
Zekuan Xu
Phase 2
30
Nanjing
2024-06-14
Recruiting
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06574568Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd
Phase 1
70
Beijing, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Dalian, Jinan
2024-06-14
Recruiting
Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease
NCT05831085Coronary Artery Stenosis
Duk-Woo Park, MD
Not applicable
1,500
Beijing, Hanzhou
2024-06-14
Recruiting
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
NCT05303285Ankylosing Spondylitis (AS)
Tongji Hospital
Phase 4
100
Wuhan
2024-06-14
Recruiting
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
NCT06532539Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
Shandong Cancer Hospital and Institute
Phase 2
30
Jinan
2024-06-13
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
NCT06437509Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
66
Shanghai
2024-06-13
Recruiting
China Healthy Aging Cohort Study
NCT06472674Age Problem, Disability, Dementia, Death
Xuanwu Hospital, Beijing
Observational
6,780
Beijing
2024-06-13
Recruiting
The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy
NCT06461377Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
The First Affiliated Hospital with Nanjing Medical University
Phase 4
50
Nanjing
2024-06-13
Active, closed
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer
NCT07371910Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
200
Guangzhou
2024-06-12
Recruiting
Spinal Versus General Anesthesia on Postoperative Pulmonary Complications
NCT06425627Pulmonary Complication, Anesthesia, Hip Fractures
Tongji Hospital
Not applicable
40
Wuhan
2024-06-12
Recruiting
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in ฮ’-thalassaemia Patients.
NCT06655662ฮ’-thalassemia
Shenzhen Hemogen
Phase 1
8
Guangxi, Shenzhen
2024-06-12
Recruiting
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
NCT06813365Nonsmall-cell Lung Cancer
Dizal Pharmaceuticals
Phase 1
300
Beijing
2024-06-12
Recruiting
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
NCT06409702Newly Diagnosed, High Risk, MRD, Multiple Myeloma
The First Affiliated Hospital of Soochow University
Phase 4
59
Suzhou
2024-06-12
Recruiting
Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin ฮฑvฮฒ3 Positive Expression
NCT06375564Refractory Solid Tumor
The First Affiliated Hospital of Xiamen University
Phase 1
20
Xiamen
2024-06-12
Recruiting
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
NCT06255392Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
200
Guangzhou
2024-06-12
Recruiting
A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging
NCT06769893RCC, Renal Cell Cancer
Xijing Hospital
Not applicable
60
Xi'an, China
2024-06-12
Recruiting
Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis
NCT06414135Systemic Sclerosis
Liangjing Lu
Phase 1
6
Shanghai
2024-06-12
Recruiting
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
NCT06611813HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Shanghai, รœrรผmqi, Xi'an
2024-06-11
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
550
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2024-06-11
Recruiting
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
NCT06389292Acute Myeloid Leukemia
Ascentage Pharma Group Inc.
Phase 3
486
Tianjin, Hangzhou
2024-06-11
Active, closed
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621Triple Negative Breast Cancer(TNBC)
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Recruiting
Exploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Based on Multimodal Imaging Technology
NCT06557720Drug Resistant Epilepsy, Magnetic Resonance Imaging, Electroencephalogram (EEG)
Xijing Hospital
Observational
50
Xi'an
2024-06-11
Recruiting
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
NCT06398444Advanced Neuroendocrine Neoplasm
Sinotau Pharmaceutical Group
Phase 2/3
85
Shanghai
2024-06-11
Recruiting
Study on the Safety and Efficacy of Sodium Phosphate Powder for Intestinal Preparation in People Aged 50 to 70 Years Old
NCT06652906Physical Examination
RenJi Hospital
Phase 2
8
Shanghai
2024-06-11
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
NCT06482801Liver Cancer, Antibody
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
90
Guangzhou
2024-06-10
Recruiting
Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer
NCT05892289Stomach Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
42
Guangzhou
2024-06-10
Recruiting
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NCT06481241Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
77
Tianjin
2024-06-10
Active, closed
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076Lung Cancer, Non-Small Cell
GlaxoSmithKline
Phase 3
88
Chengdu, Hangzhou, Hefei, Nanjing, Shanghai
2024-06-10
Recruiting
Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability
NCT06430554Respiratory Distress Syndrome, Positive-Pressure Respiration, Mechanical Ventilation
Zhongda Hospital
Observational
40
Nanjing
2024-06-08
Recruiting
A Substudy of the Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
NCT06881498Bone Tumor, Acute Normovolemic Hemodilution, Goal-Directed Fluid Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
32
Hangzhou
2024-06-07
Recruiting
The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
NCT06459141Acute Normovolemic Hemodilution, Bone Tumor, Goal-Directed Fluid Therapy, Transfusion
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
150
Hangzhou
2024-06-07
Active, closed
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
406
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan
2024-06-07
Recruiting
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
NCT06976177Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Phase 2
310
Hangzhou
2024-06-07
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06437522Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
46
Shanghai
2024-06-07
Recruiting
The Effect and Mechanism of Xiqing Regulating Intestinal Homeostasis on Drug Efficacy of Chronic Kidney Disease
NCT07182942CKD, Drug Effect
Chujin Cao
Phase 4
120
Wuhan
2024-06-07
Recruiting
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
NCT06456892Rhabdomyosarcoma, Pediatric Cancer
Sun Yat-sen University
Phase 1/2
82
Guangzhou
2024-06-06
Recruiting
A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B
NCT06425341Chronic Hepatitis B
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
369
Guangzhou
2024-06-06
Recruiting
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
NCT06885814Esophageal Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2
30
Guangzhou
2024-06-06
Recruiting
Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort
NCT06399185Urinary Catheter, Catheter-related Bladder Discomfort, Dexmedetomidine, Esketamine
Peking University First Hospital
Phase 4
1,740
Beijing, Shenzhen
2024-06-06
Recruiting
Multimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease
NCT06452862Diabetic Kidney Disease
Shengjing Hospital
Observational
150
Shenyang
2024-06-06
Recruiting
Mobile Applet for Weight Management in Obese Heart Failure Patients
NCT06455878Heart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection Fraction
Heart Health Research Center
Not applicable
830
Beijing, Guangzhou, Langfang, Jixi, Luoyang, Shangqiu, Xinyang, Zhengzhou
2024-06-06
Recruiting
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
NCT06407947Multiple Myeloma
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
10
Shanghai
2024-06-06
Recruiting
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
NCT06440915Aspergillosis Invasive, Mucormycosis
Shanghai Children's Medical Center
Not applicable
200
Shanghai
2024-06-06
Recruiting
A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
NCT06383871Advanced Malignant Tumour
Shandong Suncadia Medicine Co., Ltd.
Phase 1
233
Tianjin
2024-06-06
Recruiting
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
NCT06477614Solid Tumor, Adult, DC
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
60
Guanzhou
2024-06-05
Recruiting
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
NCT06528847Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
62
Shanghai
2024-06-05
Recruiting
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
NCT06277219Advanced Solid Tumor
Latticon Antibody Therapeutics, Inc
Phase 1/2
150
Jinan, Hangzhou
2024-06-05
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population
NCT06724848COPD
AstraZeneca
Observational
850
Beijing, Changsha, Chengdu, Guangzhou, Hefei, Nanjing, Nanning, Shanghai
2024-06-05
Not yet open
Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
NCT06453889Lung Cancer
Shanghai Chest Hospital
Not applicable
10
Shanghai
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Recruiting
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
NCT06450067B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
Observational
200
Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu
2024-06-05
Recruiting
Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors
NCT06195293Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2024-06-04
Rows per page Showing 12501–12600 of 19052
Previous 124 125 126 127 128 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=126

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.